Mitokinin Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 11

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $110M

Mitokinin General Information

Description

Developer of a small molecule therapeutics designed to increase the activity of active-form PINK1. The company offers compounds that do not interfere with the endogenous regulation of PINK1 and its team of neuroscientists, chemists, pharmacologists, and administrative professionals is dedicated to delivering disease-modifying therapies in this field, enabling healthcare providers to treat neurodegenerative disease with the advancement of therapies.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 953 Indiana Street
  • San Francisco, CA 94107
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 953 Indiana Street
  • San Francisco, CA 94107
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mitokinin Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 04-Oct-2023 $110M Completed Generating Revenue
4. Grant 25-Oct-2019 Completed Generating Revenue
3. Early Stage VC (Series A1) 01-Jan-2019 Completed Generating Revenue
2. Grant 01-Jan-2018 $225K $4.53M Completed Generating Revenue
1. Early Stage VC (Series A) 12-Sep-2017 $4.53M $4.53M Completed Startup
To view Mitokinin’s complete valuation and funding history, request access »

Mitokinin Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1
Series A
To view Mitokinin’s complete cap table history, request access »

Mitokinin Patents

Mitokinin Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260356839-A1 Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof Pending 19-Aug-2022
WO-2024040267-A2 Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof Inactive 19-Aug-2022
WO-2024040267-A3 Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof Inactive 19-Aug-2022
WO-2024040266-A2 Disubstituted benzoimidazole and indole analogs as modulators of pink1 Inactive 19-Aug-2022
WO-2024040266-A3 Disubstituted benzoimidazole and indole analogs as modulators of pink1 Inactive 19-Aug-2022 C07D471/04
To view Mitokinin’s complete patent history, request access »

Mitokinin Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mitokinin Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Michael J. Fox Foundation Limited Partner
Mission Bay Capital Venture Capital Minority
Mission BioCapital Venture Capital Minority
Novartis Institutes for BioMedical Research Corporation Minority
Pfizer Ventures Corporate Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Mitokinin FAQs

  • When was Mitokinin founded?

    Mitokinin was founded in 2017.

  • Where is Mitokinin headquartered?

    Mitokinin is headquartered in San Francisco, CA.

  • What is the size of Mitokinin?

    Mitokinin has 11 total employees.

  • What industry is Mitokinin in?

    Mitokinin’s primary industry is Drug Discovery.

  • Is Mitokinin a private or public company?

    Mitokinin is a Private company.

  • What is the current valuation of Mitokinin?

    The current valuation of Mitokinin is .

  • What is Mitokinin’s current revenue?

    The current revenue for Mitokinin is .

  • How much funding has Mitokinin raised over time?

    Mitokinin has raised $9.5M.

  • Who are Mitokinin’s investors?

    Michael J. Fox Foundation, Mission Bay Capital, Mission BioCapital, Novartis Institutes for BioMedical Research, and Pfizer Ventures are 5 of 9 investors who have invested in Mitokinin.

  • When was Mitokinin acquired?

    Mitokinin was acquired on 04-Oct-2023.

  • Who acquired Mitokinin?

    Mitokinin was acquired by AbbVie.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process